Alembic Pharma Share Price Climbs on June 8, 2026 After Canada JV with Difgen Holdings and USFDA Approval for Haloperidol Tablets

Alembic Pharma share price gained 0.89% to Rs 744.95 on June 8, 2026, outperforming a weak broader market, after two positive corporate developments: the signing of a shareholders’ agreement for a 45% stake in a Canadian corporation (a joint venture with Difgen Holdings to develop and market pharmaceutical products in Canada), and the receipt of a final US FDA approval for Haloperidol Tablets with an estimated US market size of $27 million.

The Alembic Pharma share price touched an intraday high of Rs 754.15, gaining Rs 6.55 from its previous close of Rs 738.40. Both catalysts were announced within two days of each other (June 5-6, 2026) and collectively improve the company’s international revenue pipeline, adding near-term optimism at a time when Alembic Pharma has been trading well below its 52-week high.

Click Here – Get Free Investment Predictions

Parameter	Details
NSE Symbol	APLLTD
CMP (June 8, 2026)	Rs 744.95
Previous Close	Rs 738.40
Change	+0.89% (+Rs 6.55)
Open	Rs 742.75
Intraday High	Rs 754.15
Intraday Low	Rs 732.65
52-Week High	Rs 1,107.90
52-Week Low	Rs 635.80
Market Cap (approx.)	Rs 14,514 Cr
P/E Ratio (TTM)	~22.62
Promoter Holding	69.74%
Sector	Pharmaceuticals

What Triggered the Alembic Pharma Share Price Gain Today

Canada Joint Venture with Difgen Holdings

On June 6, 2026, Alembic Pharmaceuticals signed a shareholders’ agreement to acquire a 45% stake in a Canadian corporation through a joint venture with Difgen Holdings. The JV will focus on developing and marketing pharmaceutical products in Canada. This is a meaningful strategic move for Alembic Pharma, which has been building its regulated markets presence beyond the US and Europe. Canada represents a stable, high-value generics market with a well-established regulatory framework through Health Canada. The partnership with Difgen Holdings brings local market expertise and distribution infrastructure that Alembic can leverage to accelerate product launches without the full upfront capital cost of a standalone entry.

USFDA Final Approval for Haloperidol Tablets

On June 5, 2026, Alembic Pharmaceuticals received a final US FDA approval for Haloperidol Tablets, with an estimated US market size of $27 million per year. Haloperidol is an antipsychotic medication used to treat schizophrenia and other psychiatric conditions, and the approval adds a commercially viable generic to Alembic’s US product portfolio. This follows Alembic’s appointment of Tushar Mehta as Head of R&D (API) on June 3, 2026, signalling continued investment in the research and manufacturing pipeline that underpins future regulatory approvals.

Alembic Pharma Financial Performance

Check Alembic Pharma Fundamentals Live on the Univest Screener

Alembic Pharmaceuticals reported Q3 FY26 revenue of Rs 1,876.31 crore and net profit of Rs 131.95 crore (December 2025 quarter). The company’s promoter holding stands firm at 69.74% as of March 2026, reflecting confidence from the Amin family promoter group that has led the company since its founding in 1907. At a P/E of approximately 22.62 and a 52-week low of Rs 635.80, the Alembic Pharma share price at Rs 744.95 represents a meaningful discount to its 52-week high of Rs 1,107.90.

Metric	Q3 FY26 (Dec 2025)
Revenue	Rs 1,876.31 Cr
Net Profit	Rs 131.95 Cr
Market Cap (approx.)	Rs 14,514 Cr
P/E Ratio (TTM)	~22.62
Promoter Holding	69.74%
52-Week High / Low	Rs 1,107.90 / Rs 635.80

Alembic Pharma Share Price Technical View

Download the Univest iOS App or Univest Android App to track Alembic Pharma share price live and receive pharma sector alerts from Univest.

The Alembic Pharma share price is trading near Rs 744.95, with an intraday high of Rs 754.15 suggesting near-term buying interest on the dual catalyst news. The stock remains approximately 33% below its 52-week high of Rs 1,107.90, indicating significant room for recovery if the regulatory approval pipeline continues to deliver. Immediate resistance is seen near Rs 754-760 and support near Rs 732 (today’s low). The 52-week low of Rs 635.80 serves as the key longer-term support level.

Conclusion

Alembic Pharma share price gained 0.89% to Rs 744.95 on June 8, 2026, driven by two meaningful positives: a 45% stake in a Canada JV with Difgen Holdings to develop and market pharmaceutical products, and USFDA approval for Haloperidol Tablets worth an estimated US$27 million market. Both developments strengthen Alembic’s international regulated market presence and add visibility to the product pipeline. The stock is trading at a 33% discount to its 52-week high. Investors should consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions on Alembic Pharma Share Price

Why is Alembic Pharma share price rising today on June 8, 2026?

Ans. Alembic Pharma share price is rising 0.89% to Rs 744.95 on June 8, 2026, driven by two catalysts: a joint venture with Difgen Holdings in Canada where Alembic acquired a 45% stake to develop and market pharma products, and a final US FDA approval for Haloperidol Tablets with an estimated US$27 million annual market size.

What is the Alembic Pharma Canada JV with Difgen Holdings?

Ans. On June 6, 2026, Alembic Pharmaceuticals signed a shareholders agreement to acquire a 45% stake in a Canadian corporation through a joint venture with Difgen Holdings. The JV is focused on developing and marketing pharmaceutical products in Canada, giving Alembic Pharma access to a regulated high-value generics market with Difgen’s local expertise and distribution infrastructure.

What USFDA approval did Alembic Pharma receive?

Ans. Alembic Pharmaceuticals received a final US FDA approval for Haloperidol Tablets on June 5, 2026. Haloperidol is an antipsychotic medication used to treat schizophrenia and related psychiatric conditions. The estimated US market size for this product is approximately US$27 million annually, adding a commercially viable generic to Alembic’s US portfolio.

What is Alembic Pharma’s 52-week high and low share price?

Ans. Alembic Pharma’s 52-week high is Rs 1,107.90 and the 52-week low is Rs 635.80. At the current Alembic Pharma share price of Rs 744.95 on June 8, 2026, the stock is trading approximately 33% below its one-year peak, indicating room for recovery as the regulatory pipeline delivers approvals and international partnerships expand.

What is Alembic Pharma’s market cap and P/E ratio?

Ans. Alembic Pharmaceuticals has a market capitalisation of approximately Rs 14,514 crore and a trailing P/E ratio of approximately 22.62. For Q3 FY26 (December 2025 quarter), the company reported revenue of Rs 1,876.31 crore and net profit of Rs 131.95 crore. Promoter holding is 69.74%, reflecting strong family promoter commitment since the company’s founding in 1907.

Should I buy Alembic Pharma shares today?

Ans. This article does not constitute investment advice. Alembic Pharma share price has gained on positive news of a Canada JV and USFDA approval. Investors should assess the full pipeline, US market contribution, regulatory risks, and broader pharma sector dynamics before making a decision. Consult a SEBI-registered financial advisor for personalised guidance.

What are the key risks for Alembic Pharma investors to watch?

Ans. Key risks for Alembic Pharma include US FDA inspection outcomes at manufacturing facilities, pricing pressure in the US generics market, slower-than-expected product launches in Canada, fluctuations in domestic API and formulation margins, and broader pharmaceutical regulatory changes in key markets. The stock has already corrected 33% from its 52-week high, reflecting some of these concerns in the current price.

What is Alembic Pharma’s dividend and promoter holding?

Ans. Alembic Pharmaceuticals declared a dividend of Rs 11 per share for FY25. Promoter holding stands at 69.74% as of March 2026. The Amin family group has maintained consistent promoter involvement since the company was founded in 1907, and the stable high promoter holding signals management confidence in the long-term business outlook.